ArticleEuropean radiology2023
Infliximab response associates with radiologic findings in bio-naïve Crohn's disease.
Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The predictive value of machine learning for the response to anti-TNF-α therapy in patients with Crohn's disease: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Artificial intelligence in inflammatory bowel disease: From current evidence, clinical translation, and the road to precision medicine.Chinese medical journal · 2026Review
- Development of a stacking model for personalized treatment of Crohn's disease: leveraging routine clinical features to forecast infliximab response.Frontiers in pharmacology · 2026Article
- Psoas muscle CT radiomics-based machine learning models to predict response to infliximab in patients with Crohn's disease.Annals of medicine · 2025Article
- Expanding the role of radiomics and artificial intelligence in the management of inflammatory bowel disease: Insights, opportunities, and challenges.World journal of gastroenterology · 2025Article
- Imaging monitoring contributes to the "treat-to-target" strategy in the management of Crohn's disease.World journal of gastroenterology · 2025Article
- Correlation between radiomic features of Crohn's disease and secondary loss of response to infliximab.World journal of gastroenterology · 2025Article
- Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn's disease patients.World journal of gastroenterology · 2025Article
- ChatGPT as an effective tool for quality evaluation of radiomics research.European radiology · 2025Article
- Radiomics nomogram based on dual-energy CT-derived iodine maps: evaluation of mucosal healing in patients with Crohn's disease.Abdominal radiology (New York) · 2025Article
- Robustness of radiomics among photon-counting detector CT and dual-energy CT systems: a texture phantom study.European radiology · 2025Article
- Computed tomography enterography-based radiomics for assessing mucosal healing in patients with small bowel Crohn's disease.World journal of gastroenterology · 2025Article
- Development and Validation of a CTE-Based Radiomics Nomogram for Predicting Clinical Adverse Outcomes in Patients with Stricturing Crohn's Disease.Journal of inflammation research · 2025Article
- CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn's disease.La Radiologia medica · 2024Article
- Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn's Disease Patients: A Multicentre, Retrospective Study.Journal of inflammation research · 2024Article
- Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesSince a reliable model for predicting infliximab (IFX) benefits in bio-naïve Crohn's disease (CD) is still lacking, we constructed a magnetic resonance enterography (MRE)-based model to predict the risk of loss of response to IFX in bio-naïve patients with CD.
methodsThis retrospective multicenter study enrolled 188 bio-naïve patients with CD who underwent MRE before IFX therapy. Therapeutic outcomes were determined based on clinical symptoms and endoscopic findings within 52 weeks. The areas of bowel wall segmentation were decided by two experienced radiologists in consensus. Texture features were extracted using the least absolute shrinkage and selection operator, and a radiomic model was built using multivariate logistic regression. The model performance was validated by receiver operating characteristic, calibration curve, and decision curve analysis.
resultsThe area under the curve of radiomic model was 0.88 (95% confidence interval: 0.82-0.95), and the model provided clinical net benefit in identifying the loss of response to IFX and exhibited remarkable robustness among centers, scanners, and disease characteristics. The high-risk patients defined by the radiomic model were more likely to develop IFX nonresponse than low-risk patients (all p < 0.05).
conclusionsThis novel pretreatment MRE-based model could act as an effective tool for the early estimation of loss of response to IFX in bio-naïve patients with CD. KEY POINTS: • Magnetic resonance enterography model guides infliximab therapy in Crohn's disease. • The model presented significant discrimination and provided net clinical benefit. • Model divided patients into low- and high-risk groups for infliximab failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.